4 citations
,
January 2023 in “Skin health and disease” This study shows that in a mouse model of Alopecia Areata, selective JAK1 inhibition facilitated hair regrowth and inflammation resolution while potentially offering a better safety profile compared to pan-JAK inhibition.
2 citations
,
November 2025 in “Journal of the American Academy of Dermatology” In this randomized, placebo-controlled trial, adults with severe chronic alopecia areata who received deuruxolitinib showed significant hair regrowth compared to placebo over 24 weeks, and the treatment was generally well-tolerated, though long-term effects remain unexamined.
September 2019 in “Journal of Investigative Dermatology” In this study, dose-response modeling predicted that once-daily abrocitinib doses of 100 mg and 200 mg may provide a clinically meaningful response in treating moderate-to-severe atopic dermatitis compared to placebo.
34 citations
,
June 2020 in “British journal of dermatology/British journal of dermatology, Supplement” In this study, researchers observed that follicular damage and stem cell loss in frontal fibrosing alopecia may be mediated by immune attacks at the bulge region, suggesting potential for JAK/STAT-targeting treatments to prevent progression.
September 2025 in “Chinese Journal of Chromatography” This study developed a method using ultra-high performance liquid chromatography-mass spectrometry (UHPLC-MRM-IDA-EPI) for the rapid and sensitive detection of 13 JAK inhibitors in anti-alopecia cosmetics, showing excellent separation and accurate quantification with high recovery rates in tested matrices.
24 citations
,
January 2018 in “International Journal of Trichology” This study found that oral tofacitinib was effective in promoting hair regrowth in patients with alopecia universalis, although further controlled studies are recommended to confirm its safety and efficacy.
48 citations
,
November 2017 in “Journal of the American Academy of Dermatology” Tofacitinib 2% ointment helped hair regrow in 3 out of 10 patients with alopecia areata, but caused side effects like scalp irritation and raised cholesterol in some.
14 citations
,
March 2021 in “Actas Dermo-Sifiliográficas” This review discusses the JAK/STAT signaling pathway's role in immune-mediated skin diseases and examines the efficacy and safety of JAK inhibitors for treating vitiligo and alopecia areata, but reports no new clinical results.
March 2026 in “Mendeley Data” No results are reported in this dataset abstract, which details supplementary materials for a systematic review and meta-analysis on oral Janus kinase inhibitors' effectiveness and safety in children with alopecia areata, aiming to enhance transparency and interpretation of the main article's findings.
March 2026 in “Mendeley Data” In this systematic review and meta-analysis on participants aged 12 and under with alopecia areata, the authors provide supplementary tables and figures, including pooled outcomes for hair regrowth and safety of oral Janus kinase inhibitors, supporting the main findings on their effectiveness and safety.
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” This study found that JAK1 and JAK2 inhibitors increase β-catenin activity in human hair follicle cells, suggesting an additional therapeutic mechanism for treating severe alopecia areata.
November 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” In this study, treatment with oral JAK inhibitors was associated with improved disease outcomes in 80.6% of patients with refractory lichen planopilaris over a mean duration of 5 months.
7 citations
,
March 2023 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” This letter discusses the potential of the Janus kinase 1 inhibitor abrocitinib for treating oral lichen planus but provides no new research findings.
17 citations
,
January 2019 in “Journal of cutaneous medicine and surgery” This review discusses the potential of JAK inhibitors for treating alopecia areata and reports case study evidence of their effectiveness, but formal clinical trials are needed for more definitive conclusions.
3 citations
,
June 2025 in “Archives of Dermatological Research” In this review, researchers found that TNF-α, IL-17, and JAK inhibitors show the most promise for stabilizing and resolving scarring alopecias, with IL-23 and Interferon Alpha Receptor 1 inhibitors also providing some benefits in managing these hair loss conditions.
March 2026 in “Immunological Medicine” This review discusses the use of Janus kinase inhibitors for severe alopecia areata in Japan, noting their effectiveness in some patients but highlighting the need for new therapies due to non-responsiveness and relapse in others; it reports no new clinical results.
This study found that self-monitoring blood pressure among pregnant women with hypertension did not significantly improve clinical outcomes compared to usual care, though women reported positive cognitive and emotional responses.
September 2023 in “Journal of The American Academy of Dermatology” At Week-104 of the BRAVE-AA2 trial, this study found that 90.2% of severe alopecia areata patients who continued on baricitinib 4mg maintained hair regrowth, whereas 45.2% of those who reduced their dosage to 2mg experienced a loss of treatment benefit.
November 2022 in “The journal of investigative dermatology/Journal of investigative dermatology” This study reported that IL-15 promotes human hair growth and protects hair follicle immune privilege, potentially stabilizing alopecia areata treatment outcomes when selectively stimulating IL-15Rα signaling.
6 citations
,
October 2024 in “Journal of Family Medicine and Primary Care” This systematic review details monitoring and safety guidelines for primary care physicians regarding Janus kinase and tyrosine kinase 2 inhibitors used in treating inflammatory skin conditions, emphasizing their efficacy and the importance of updated knowledge due to associated box warnings and increasing use.
December 2025 in “Actas Dermo-Sifiliográficas” This review analyzes the mechanism and evidence supporting the approved use of ritlecitinib, a JAK3/TEC kinase inhibitor, for treating severe alopecia areata in patients aged 12 and older, highlighting its role in the changing therapeutic landscape of this immune-mediated disease.
23 citations
,
October 2024 in “British Journal of Dermatology” In this study, ritlecitinib showed sustained effectiveness and a favorable safety profile in treating alopecia areata in patients aged 12 and older over 24 months, with improvements observed in hair and eyebrow regrowth and patient satisfaction.
April 2025 in “Acta Dermato Venereologica” In this real-world study, JAK inhibitors like abrocitinib and tofacitinib led to substantial hair regrowth in 61% of alopecia areata patients over a median of 16 months, with 75% of non-responders achieving regrowth after switching medications; however, two serious adverse events were noted.
September 2023 in “Dermatology and Therapy” In a Belgian cohort study, nearly 90% of alopecia areata patients treated with oral baricitinib experienced hair regrowth, with more than 70% achieving a favorable SALT score, particularly in patchy cases, though some relapsed post-treatment. No serious adverse events were noted.
59 citations
,
September 2021 in “Journal of Allergy and Clinical Immunology” This study found IL-17/IL-36 signaling to be predominant in both endotypes of Netherton syndrome, with distinct molecular profiles between NS-ILC and NS-SE lesions, offering potential therapeutic targets.
8 citations
,
July 2024 in “European journal of medical research” This study reported that alopecia areata following COVID-19 vaccination is rare, occurring mostly after the first dose and associated with several vaccine types, particularly Pfizer.
4 citations
,
April 2024 in “Journal of Drugs in Dermatology” In this case report, a severe case of pediatric alopecia areata was treated with topical ruxolitinib, a Janus kinase inhibitor, highlighting the limited but promising evidence for this treatment in children.
1 citations
,
April 2018 in “Journal of Investigative Dermatology” This study found that FZD2 is crucial for hair follicle formation and postnatal growth in mice and has a novel role in regulating early epidermal development, including stratification and cornification.
December 2025 in “Педиатрическая фармакология” In this pediatric retrospective study, tofacitinib (a Janus kinase inhibitor) improved the severity of alopecia and quality of life more effectively than traditional treatment methods, with significant reductions in alopecia severity score and dermatology life quality index over 16 weeks.
October 2025 in “Postgraduate Medical Journal” This study found that among various JAK inhibitors for severe alopecia areata, baricitinib_4 mg demonstrated significant efficacy with high precision, while deuruxolitinib_12 mg showed the best efficacy but with wider confidence intervals, providing clinicians valuable information for treatment selection.